Medtronic Takes Manufacturing to Galway
Medtronic is investing €13 million in a high-tech 20,000 square foot facility in Galway, Ireland that will be the manufacturing site for the company’s drug-coated balloon. About 8000 square feet of space will be dedicated to the manufacturing of the IN.PACT Admiral device, which is used for the treatment of peripheral artery disease.
Ireland Remains Competitive in Medical Device Sector“Our global market leadership in DCB [drug-coated balloons] is driving the need to open the new facility here in Galway to provide more patients access to this highly efficacious and safe treatment option for peripheral arterial disease,” said Tony Semedo, senior vice president and president of the Aortic & Peripheral Vascular business at Medtronic in a company release. “Our Galway operations and staff have very specific expertise in this area, which is the platform for this announcement. Once fully operational, this facility will be the only DCB manufacturing area of its kind in Medtronic worldwide.”
The company selected Galway due to its on-site expertise in combination products for its coronary business. The facility will be home to about 100 employees who have backgrounds in quality and manufacturing engineering, and supply chain and production management.
Related Articles
-
Share your research, experience and expertise with your peers at the upcoming Medtech Advanced Manufacturing Conference and Medtech Supply Chain Intelligence Summit. Call for abstracts is now open.
-
Medtronic will invest up to $75 million and immediately begin co-promotion of CathWorks’ FFRangio System for the noninvasive diagnosis of CAD in the U.S., Europe and Japan, where it is commercially available.
-
Excess humidity can affect a pharmaceutical’s structure, chemical stability and dissolving rate, and this moisture can come in contact with product at multiple points throughout production and shipping. Fortunately, new technologies are making it easier for manufacturers and shippers to…
-
“Many medical device and life sciences companies are still carrying out manual validation processes, using paper-based scripts, screen shots and pdfs. However, regulatory bodies, such as the FDA, are encouraging companies to take a more automated approach using computer system…
About The Author
MedTech Intelligence Staff
The MedTech Intelligence staff consists of freelance journalists and industry contributing writers with decades of experience in covering medical device issues under the categories of business, market trends, product development, quality, regulatory, and operations.
You can contact our writing staff via our Contact Page.